Efficacy and safety of oxycodone/naloxone as add‐on therapy to gabapentin or pregabalin for the management of chemotherapy‐induced peripheral neuropathy in Korea

Aims To investigate the efficacy and safety of oxycodone/naloxone in patients with chemotherapy‐induced peripheral neuropathy (CIPN) inadequately controlled with pregabalin or gabapentin. Methods This 4‐week, multicenter, interventional, single‐arm phase IV study included 72 Korean patients with CIP...

Full description

Saved in:
Bibliographic Details
Published in:Asia-Pacific journal of clinical oncology 2018-10, Vol.14 (5), p.e448-e454
Main Authors: Kim, Bong‐Seog, Jin, Jong‐Youl, Kwon, Jung Hye, Woo, In Sook, Ko, Yoon Ho, Park, Suk‐Young, Park, Hye‐Jeong, Kang, Jin Hyung
Format: Article
Language:English
Subjects:
Cancer
Chemotherapy
Gabapentin
Naloxone
neuralgia
Neurotoxicity
Oxycodone
Pain
Peripheral neuropathy
pregabalin
Safety
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Aims To investigate the efficacy and safety of oxycodone/naloxone in patients with chemotherapy‐induced peripheral neuropathy (CIPN) inadequately controlled with pregabalin or gabapentin. Methods This 4‐week, multicenter, interventional, single‐arm phase IV study included 72 Korean patients with CIPN inadequately controlled with pregabalin or gabapentin (Numeric Rating Scale 0–10; NRS ≥4 at baseline). In addition to pregabalin or gabapentin at existing doses, patients received 20/10 mg/day oxycodone/naloxone (up‐titrated to 80/40 mg/day as needed). The primary endpoint was change in NRS score after 4 weeks. Secondary endpoints included Functional Assessment of Cancer Therapy/Gynecologic Oncology Group‐Neurotoxicity (FACT/GOG‐NTX) scores and safety assessments. Results The mean ± standard deviation (SD) dose of oxycodone/naloxone was 23.3 ± 7.5 mg/day. At week 4, NRS score reduction was 1.29 ± 1.84 points (21.4% reduction; P 
ISSN:1743-7555
1743-7563
DOI:10.1111/ajco.12822